Rockwell Medical, Inc.

ROCKWELL MEDICAL INC's next confirmed earnings release is scheduled for November 12, 2026.

As of June 30, 2026, ROCKWELL MEDICAL INC maintains a current ratio of 3.25, meaning it holds 3.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 39.71, indicating elevated leverage, while an interest coverage ratio of -2.14 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, ROCKWELL MEDICAL INC posted a negative return on equity (ROE) of -15.53, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -9.32, reflecting losses generated across the asset base. The company generates approximately 339,782.89 in revenue per employee across its workforce of 178.75, a quick read on workforce productivity versus industry peers. Inventory turnover of 16.37 indicates how many times ROCKWELL MEDICAL INC sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on June 30, 2026, ROCKWELL MEDICAL INC's stock has declined approximately 25.69% over the past 52 weeks. The 50-day moving average sits at 0.65, while the 200-day moving average is 0.83.

These figures cover the twelve months ended June 30, 2026. EBITDA reached -2.13M, while operating income came in at -3.96M.

As of June 30, 2026, ROCKWELL MEDICAL INC holds 21.70M in cash and equivalents against 12.20M in total debt, resulting in a net debt position of -1.33M. Total book value stands at 30.71M, with working capital of 22.05M providing operational flexibility.

ROCKWELL MEDICAL INC produced 2.54M in operating cash flow over the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, ROCKWELL MEDICAL INC posted a gross margin of 17.71, reflecting its pricing power and cost economics. The operating margin of -6.52 and net profit margin of -7.33 provide insight into operational efficiency.